A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C)in Patients With Refractory Primary Immune Thrombocytopenia
A legfontosabb adatok
- Ki végzi
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Hol
- Wuhan (Kína)A helyszín megnézése
- Azonosító
- Állapot
- Toborzás még nem indult
- Fázis
- Korai 1. fázis
- Résztvevők
- 27 fő, tervezett
- Kezdés
- 2026. febr. 20.
- Várható befejezés
- 2029. márc. 1.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- QT-019C
- A regiszteradat frissítve
- 2026. február 17.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with primary immune thrombocytopenia (ITP, a low platelet count caused by the immune system) that did not respond to earlier treatment. It tests QT-019C, a donor CAR T-cell therapy that targets CD19 and BCMA.
- Életkor
- 18 to 75 years
- Nem
- All sexes
- A betegség stádiuma
- Primary ITP diagnosed at least 6 months ago and refractory (did not respond, came back, or could not be kept under control). Platelet count must be below 30×10^9/L in two tests within 15 days before treatment, at least 7 days apart. Heart, kidney, liver, blood and oxygen levels must be basically normal.
- Korábbi kezelés
- People must have had first-line treatment (corticosteroids or immunoglobulins) and/or second-line treatment (such as eltrombopag, romiplostim, rituximab or spleen removal) without enough effect. People who have had gene-modified cell therapy (TCR-T, CAR-T, CAR-NK) cannot join. Recent rituximab, CD19- or BCMA-targeted treatment, IVIG, plasma exchange, immunosuppressants, or prednisone above 10 mg/day are not allowed within set time limits.
- Biomarker vagy leletérték
- A positive test for any anti-platelet glycoprotein autoantibody (GPIb/GPIX/GPIIb/GPIIIa/GMP140).
A részvétel fő kizáró okai
- Low platelets caused by another disease, such as myelodysplastic syndromes, aplastic anemia or other autoimmune diseases
- Serious heart disease, such as heart failure or a heart attack within 6 months
- Active hepatitis B or C, HIV, or syphilis
- Cancer within the past 5 years, except some low-risk tumors
- Blood clot in a vein or lung within 6 months, need for blood thinners, or an active infection
A regiszter feltételei, szó szerint
Mind a 18 feltétel megnézéseKevesebb
Ki vehet részt
- 1. Participants aged ≥18 years and ≤75 years, regardless of gender
- 2. Clinically diagnosed with primary immune thrombocytopenia for no less than 6 months, with platelet counts < 30×10\^9/L in two separate tests conducted within 15 days before the initiation of study treatment, with at least 7 days between the tests
- 3. Presence of any anti-platelet glycoprotein autoantibody (GPIb/GPIX/GPIIb/GPIIIa/GMP140) positive
- 4. Meet the criteria for refractory ITP: previously received first-line and/or second-line ITP treatment (first-line treatment includes corticosteroids or immunoglobulins; second-line treatment includes thrombopoietin receptor agonists (such as eltrombopag, romiplostim), rituximab, splenectomy, etc.), but ineffective (post-treatment platelet count <30×10\^9/L, or platelet count increase less than twice the baseline value, or presence of bleeding), or relapse after initial response or difficult to maintain after discontinuation
- 5. Important organ functions are basically normal during the selection period:; Echocardiogram indicates ejection fraction >50%, ECG shows no significant abnormalities; Creatinine clearance (CrCl) (Cockcroft-Gault formula) >30 mL/min; Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <3.0x the upper limit of normal (ULN); Total bilirubin (TBIL) and alkaline phosphatase (AKP or ALP) <2.0x ULN (Gilbert's syndrome <3.0x UN); Absolute lymphocyte count (ALC) >0.5x10\^9; absolute neutrophil count (ANC) >1x10\^9; hemoglobin (Hb) >60g; Oxygen saturation >92%
- 6. Female participants of childbearing potential and male participants who are partners of women of childbearing age must use medically accepted contraceptive measures or abstain for at least 12 months during and after the study treatment; female participants of childbearing age must have a negative serum HCG test within 7 days before study enrollment and must not be breastfeeding
- 7. Volunteer to participate in this clinical study, sign informed consent, demonstrate good compliance, and cooperate with follow-up
Ki nem vehet részt
- 3. History of any of the following heart diseases:; NYHA class II or IV congestive heart failure; Myocardial infarction within 6 months before signing the ICF, or having undergone coronary artery bypass grafting (CABG) or coronary artery stent implantation; Clinically significant ventricular arrhythmias or a history of unexplained syncope (excluding cases caused by vasovagal or dehydration); History of severe non-ischemic cardiomyopathy
- 4. Patients who have previously received gene-modified cell therapies such as TCR-T, CAR-T, CAR-NK, etc
- 7. Subjects who have used prednisone > 10 mg/day or have had dosage adjustments within 2 weeks before screening. Oral glucocorticoid treatment equivalent to ≤ 10 mg/day of prednisone is acceptable at enrollment, provided the dosage has been stable for at least 2 weeks before enrollment
- 8. Subjects with a history of symptomatic deep vein thrombosis or pulmonary embolism within 6 months before screening, or who currently require anticoagulation therapy
- 9. Subjects with a history of any organ system malignancy (except well-prognosed tumors such as localized basal cell carcinoma of the skin, cervical carcinoma in situ, ductal carcinoma in situ of the breast, follicular or papillary thyroid carcinoma, etc.) within the past 5 years, regardless of whether there is evidence of local recurrence or metastasis; or known concomitant life-threatening diseases
- 10. Subjects with any active infection or any infection requiring systemic anti-infective treatment within 30 days before screening
- 1. Secondary thrombocytopenia caused by myelodysplastic syndromes, splenic hyperfunction, autoimmune diseases, early aplastic anemia, atypical aplastic anemia, and thrombotic thrombocytopenic purpura, among other causes
- 2. Bone marrow examination results during the screening phase indicate bone marrow fibrosis MF>2 (European expert consensus scoring criteria for bone marrow fibrosis, Thiele et al., 2005) or the bone marrow examination suggests the presence of other primary conditions causing thrombocytopenia aside from ITP
- 5. Patients who are positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with peripheral blood HBV DNA levels exceeding the upper limit of detection; those who are positive for hepatitis C virus (HCV) antibodies and have positive peripheral blood HCV RNA; those who are positive for human immunodeficiency virus (HIV) antibodies; and those who test positive for syphilis
- 11. Any known factors, diseases, or clinically relevant medical conditions or surgical situations that the investigator believes may place the subjects at risk, interfere with treatment compliance, study implementation, or outcomes
- 6. Subjects who have received the following drug treatments before the start of the study will be excluded:; B-cell and antibody-secreting cell (ASC) depletion therapy:; Subjects who have received anti-CD20 monoclonal antibody treatment (such as rituximab) within 3 months before screening will be excluded. If such treatment occurred more than 3 months but not more than 6 months before screening, and if the absolute count of peripheral blood CD19⁺ B cells is above the lower limit of normal (as determined by local or central laboratory), then enrollment may be allowed after confirmation by the investigator and the medical director of the sponsor (or designated representative); Subjects who have previously received simultaneous CD19-targeting and BCMA-targeting treatments will be excluded. Subjects who have received CD19-targeting or BCMA-targeting treatment (either one) within 6 months before screening will also be excluded. If such treatment occurred more than 6 months before screening, and if the absolute count of peripheral blood CD19⁺ B cells is above the lower limit of normal (as determined by local or central laboratory), then enrollment may be allowed after confirmation by the investigator and the medical director of the sponsor (or designated representative); Subjects who have used or adjusted the dosage of BTK and SyK inhibitors within 2 weeks before screening should be excluded. If the dosage has been stable for ≥ 2 weeks before screening, then they may be included; Subjects who have used or adjusted TPO-RA treatment within 2 weeks before screening should be excluded. However, those who have been on a stable dose for more than 2 weeks before screening may continue treatment; Subjects who have used IVIG or undergone plasma exchange within 4 weeks before screening should be excluded; Subjects who have used immunosuppressants (such as cyclophosphamide, mycophenolate mofetil (MMF), azathioprine, and methotrexate) within 2 weeks before lymphocyte depletion will be excluded
Nézd meg, megfelelhetsz-e
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 75 év között vagy?
Helyszínek itt: Kína
- Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, KínaContact: Heng MeiToborzás még nem indult
A vizsgálatról
Mit akar kideríteni a vizsgálat
This is an investigator-initiated trial to evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells(QT-019C) in Patients With Refractory Primary Immune Thrombocytopenia.
A vizsgálat csoportja
- QT-019C (Universal allogeneic anti-CD19/BCMA CAR T-cells)A vizsgált kezelés
The study comprises two phases: dose escalation and dose expansion. Dose escalation will follow a 3 + 3 design, and 10 to 21 participants will be included in this phase. Four dose groups (Group A, Group B, Group C, and Group D) will be set up, and the administered dose of QT-019C starts at 1×10\^6 cells/kg (Group A). Participants will undergo regular checks to evaluate the safety and tolerability of the treatment, along with data on PK, PD, and preliminary efficacy. After the completion of the dose escalation, the Safety Review Committee (SRC) will determine whether to conclude the study or select a dose level or range as the recommended dose (RD) for dose expansion research. 6 participants will be included in this phase for further assessment of QT-019C's safety and early efficacy. All participants will complete a follow-up up to 24 months.
Kezelés: QT-019C
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Refractory Primary Immune Thrombocytopenia
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Illeszkedési kérdések
- Forrás: NCT07416032: ki vehet részt
- A regiszteradat frissítve
- 2026. február 17.